SATISFACTION (2.27.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
What did you miss at RheumNow Live 2026?
Our Poster Hall features new data across:
• Psoriatic Arthritis
• Systemic Lupus Erythematosus
• Lupus Nephritis
• Vasculitis
• Polymyalgia Rheumatica
• Axial Spondyloarthritis
From Phase III trials to real-world evidence, these https://t.co/nuXGUdmwon
Dr. John Cush @RheumNow( View Tweet )
Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb https://t.co/UTPqa9erPU
Dr. John Cush @RheumNow( View Tweet )
What did you miss at RheumNow Live 2026?
Our Poster Hall features new data across:
• Psoriatic Arthritis
• Systemic Lupus Erythematosus
• Lupus Nephritis
• Vasculitis
• Polymyalgia Rheumatica
• Axial Spondyloarthritis
From Phase III trials to real-world evidence, these https://t.co/sN1BD0ccq6
Dr. John Cush @RheumNow( View Tweet )
Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27) https://t.co/1REWmod73W
Dr. John Cush @RheumNow( View Tweet )
Referral Rules to Live By (2.20.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. Highlights include referral rules, combination biologics in psoriasis, and don't use JAK inhibitors in pregnancy.
https://t.co/thzetw5jwa https://t.co/HTjWyqFqDZ
Dr. John Cush @RheumNow( View Tweet )
Peripheral manifestations are inconsistently assessed in axSpA trials. b/tsDMARDs have small-to-mod effects on peripheral Sxs & may be underestimated. Assessments in axSpA RCTs were low for periph arthritis 54%, enthesitis in 64% and dactylitis in only 10% of studies. https://t.co/cCNvU1oZMh
Dr. John Cush @RheumNow( View Tweet )
Paradoxical Reactions, Target Selection & the Future of Imaging in Psoriatic Care
At RheumNow Live, Dr. Joseph Merola presented a compelling discussion on paradoxical immune reactions in psoriatic disease. He began with a case of a 60-year-old woman with mild psoriasis who, https://t.co/AVIOO42vfP
Dr. John Cush @RheumNow( View Tweet )
What did you miss at RheumNow Live 2026?
Our Poster Hall features new data across:
• Psoriatic Arthritis
• Systemic Lupus Erythematosus
• Lupus Nephritis
• Vasculitis
• Polymyalgia Rheumatica
• Axial Spondyloarthritis
From Phase III trials to real-world evidence, these https://t.co/tp0Uncga7E
Dr. John Cush @RheumNow( View Tweet )
J Rheum full read editorial on What HLA-B27 Can—and Cannot—Tell Us!. HLA-B27 also holds prognostic and theragnostic value, given its association with greater structural damage, higher inflammatory burden, and better response to tumor necrosis factor and interleukin 17 inhib. https://t.co/3xNDtePEzn
Dr. John Cush @RheumNow( View Tweet )
Together PSO Trial - Combination Ixekizumab and Tirzepatide
Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM
Dr. John Cush @RheumNow( View Tweet )
Paradoxical Reactions, Target Selection & the Future of Imaging in Psoriatic Care
From paradoxical psoriasis to IL-23 vs IL-17 to imaging in PsA, speakers in RheumNow Live's "Decisions in Psoriatic Arthritis" pod delivered valuable, clinically relevant education.
Read Article
Together PSO Trial - Combination Ixekizumab and Tirzepatide
Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over IXE alone.
Read Article
Can I Use JAK Inhibitors During Pregnancy?
In 2020, the ACR Recommendations on Reproductive Health notably avoided firm guidance on the use of JAK inhibitors (JAKi) during pregnancy stating, "There is no available evidence regarding use or safety of the new small- molecule agents, tofacitinib, baricitinib, and apremilast, during
Read Article
RT @ericdeinMD
#RNL26
Paradoxical psoriasis with TNF
Highest in infliximab
Seen highest in IBD, particular Crohn's
Palmopustular is most common manifestation
May have overlap appearance with psoriaform with eczema, histology with psoriaform spongiotic dermatosis with https://t.co/SKQZgbLQUS
Dr. John Cush @RheumNow( View Tweet )
What did you miss at RheumNow Live 2026?
Our Poster Hall features new data across:
• Psoriatic Arthritis
• Systemic Lupus Erythematosus
• Lupus Nephritis
• Vasculitis
• Polymyalgia Rheumatica
• Axial Spondyloarthritis
From Phase III trials to real-world evidence, these
Dr. John Cush @RheumNow( View Tweet )
RT @ericdeinMD
#RNL26
Arthroplasty risks in RMD
AxSpA - Respiratory complications (OR 1.7), PNA (2.2)
SLE - complications ass w/ severity/activity. Renal failure, PE, sepsis, stroke, mortality depending on activity
PsA - complications related to co-morbidities, not PsA https://t.co/jr0hwh3CPe
Dr. John Cush @RheumNow( View Tweet )
RT @gibson_rheumPAC
Arthur Kavanaugh’s RheumNow 2026: Why Do Plain X-Rays in Psoriatic Arthritis? Thought-provoking session on the role of plain radiographs in psoriatic arthritis—not as relics of the past, but as tools that still inform prognosis, function, and long-term
Dr. John Cush @RheumNow( View Tweet )
RT @gibson_RheumPAC
Axial PsA remains an area of active investigation. IL-17 inhibitors show consistent benefit, while IL-23 data are emerging—highlighting nuances when axial symptoms drive treatment choice. #RNL26 https://t.co/XFL3Sf8iK4
Dr. John Cush @RheumNow( View Tweet )
RT @Gibson_RheumPAC
A good reminder: PsA treatment should be domain-based. Skin, peripheral joints, axial disease, and enthesitis may each favor different pathways. #RNL26 https://t.co/IUCsdlNopo
Dr. John Cush @RheumNow( View Tweet )
RT @ericdeinMD
#RNL26
Haque
TOGETHER-PsA -P3B study of IXE v IXE + Tirzepatide
BMI >27 + 1 wt related co-morbidity
-Endpts - ACR and >10% weight reduction
-ACR50 improved 33.5% compared to 20% IXE alone (p<0.05) https://t.co/KCpqbg3fHs https://t.co/zktIkdumDk
Links:
Dr. John Cush @RheumNow( View Tweet )
Maui Potpourri (2.13.2026)
Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.
- Diet & Obesity Management in Rheumatology - Uzma Haque, MD
- Mitigating risk for Rheum patients undergoing orthopedic surgery - Susan Goodman, MD
- Paradoxical skin reactions – Joseph
Obesity, Surgery, and Optimizing Patient Care
Rheumatologic care involves multidisciplinary approaches and collaboration with specialties to treat complex, systemic diseases. While many Pods at RheumNow Live are disease specific, the Pod II focused on Advancing Practice on important and emerging areas affecting rheumatologic patients. This
Read Article
Advances in RA-ILD
Dr. Jeffrey Sparks gave a state of the art update on Advances in RA-ILD, many of which he and his group have played a big part in, on Saturday at RNL26.
https://t.co/xO7hBRKeqE https://t.co/rs1MS08Svl
Links:
Dr. John Cush @RheumNow( View Tweet )
ANA Pollution (2.06.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com
Read ArticleTherapeutic Updates
The Impact of Obesity on Psoriatic Arthritis
Sponsored by Lilly Medical Affairs
Image alt text: A person indoors raises one arm in a flexed pose while holding the elbow with the opposite hand.
Is obesity common in your patients with PsA? Learn more about the intersection of disease pathogenesis between PsA and obesity and how weight intervention can affect PsA outcomes.
Read Post
Poster Hall
Recent Blogs
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do!
Read Post
Podcasts
ACR 2025 PsA Topic Podcasts Compilation 6
ACR 2025 Daily Podcasts Day4b-
ACR 2025 Daily Podcasts Day4a
